Molecular Pharmaceutics
[ASAP] Radiosynthesis and Preliminary Evaluation of [<sup>11</sup>C]SSI‑4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00273
Molecular Pharmaceutics
[ASAP] Recent Trends in the Use of Small Extracellular Vesicles as Optimal Drug Delivery Vehicles in Oncology
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00363
Molecular Pharmaceutics
[ASAP] Preparation and Bioevaluation of <sup>18</sup>F‑Labeled Small-Molecular Radiotracers <italic toggle=”yes”>via</italic> Sulfur(VI) Fluoride Exchange Chemistry for Imaging of Programmed Cell Death Protein Ligand 1 Expression in Tumors
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00355
Molecular Pharmaceutics
[ASAP] Impact of Propeptide Cleavage on the Stability and Activity of a Streptococcal Immunomodulatory C5a Peptidase for Biopharmaceutical Development
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00207
Molecular Pharmaceutics
[ASAP] Harnessing Bile for Drug Absorption through Rational Excipient Selection
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c01009
Molecular Pharmaceutics
[ASAP] ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00311
Molecular Pharmaceutics
[ASAP] Can Pure Predictions of Activity Coefficients from PC-SAFT Assist Drug–Polymer Compatibility Screening?
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00124
Molecular Pharmaceutics
[ASAP] Characterizing Silicone Oil-Induced Protein Aggregation with Stimulated Raman Scattering Imaging
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00391
Molecular Pharmaceutics
[ASAP] Molecular Recognition Study toward the Mitochondrial Electron Transport Chain Inhibitor Mubritinib and Human Serum Albumin
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00187
Molecular Pharmaceutics
[ASAP] Calcium Orthophosphate in Liposomes for Co-Delivery of Doxorubicin Hydrochloride/Paclitaxel in Breast Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00015